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Objectives: Gelatinases (MMP2 and MMP9) are expressed in giant-cell arteritis (GCA) and are thought to
play a role in vessel disruption. However, their activation status and enzymatic activity have not been
evaluated. Our aim was to investigate the distribution and proteolytic activity of gelatinases in GCA lesions at
different stages.
Methods: Expression of MMP2, MMP9, MMP2-activator MMP14 and their natural inhibitors TIMP1 and
TIMP2 was determined by real-time PCR and immunohistochemistry in temporal artery sections from 46
patients and 12 controls. MMP activation status and enzymatic activity were assessed by gelatin and film in
situ zymography.
Results: Vascular smooth muscle cells from normal specimens constitutively expressed pro-MMP2 and its
inhibitor TIMP2 with no resulting proteolytic activity. In GCA MMP2, MMP9 and MMP14 were strongly
expressed in their active form by infiltrating leucocytes. Inflamed arteries also expressed TIMP1 and TIMP2.
However, the MMP9/TIMP1 and MMP2/TIMP2 ratios were higher in patients compared with controls,
indicating an increased proteolytic balance in GCA which was confirmed by in situ zymography. Maximal
gelatinase expression and activity occurred at the granulomatous areas surrounding the internal elastic
lamina (IEL). Myointimal cells also expressed MMPs and exhibited proteolytic activity, suggesting a role for
gelatinases in vascular remodelling and repair.
Conclusions: GCA lesions show intense expression of gelatinases. Activators and inhibitors are regulated to
yield enhanced gelatinase activation and proteolytic activity. Distribution of expression and proteolytic activity
suggests that gelatinases have a major role not only in the progression of inflammatory infiltrates and vessel
destruction but also in vessel repair.
G
iant-cell arteritis (GCA) is a granulomatous vasculitis
involving large and medium-sized arteries.1
Histopathological patterns observed in involved vessels
suggest that leucocytes invade the vessel wall through the
adventitial vasa vasorum and surrounding small vessels.2 3 This
interpretation is supported by immunopathological studies
showing that adhesion molecules necessary for leucocyte
recruitment are mainly expressed by vasa vasorum.4
Inflammatory infiltrates subsequently extend towards the
adventitia and the medial layer where they undergo granulo-
matous differentiation.1 2 At this stage, inflammatory cells can
be additionally recruited through inflammation-induced neo-
vessels.4 5
To invade the vessel wall, infiltrating leucocytes need to
break the basement membrane of the vasa vasorum, and to
migrate through the interstitial matrix. As inflammatory cells
proceed across the artery wall, the internal elastic lamina (IEL)
is disrupted, allowing the progression of leucocytes, as well as
myointimal cells towards the intima.2 6 Among the proteolytic
systems participating in this process, gelatinases (MMP2 and
MMP9) may have an important role, given their elastinolytic
activity and their unique ability to degrade basement mem-
branes.7–9 Rupture of elastic fibres may lead to deleterious
consequences such as the development of aortic aneurysms, an
increasingly recognised complication of GCA.10 11 The relevance
of gelatinases in vascular destruction has been demonstrated,
indeed, in animal models of aortic aneurysms.12
As with other proteolytic systems, MMP activity is tightly
regulated at several levels. Gelatinase production is transcrip-
tionally regulated, but post-transcriptional control of enzymatic
activity is even more crucial. Gelatinases are secreted as inactive
zymogens and need to be activated by proteolytic cleavage.7 8 13
MMP2 is activated at the cell surface through a unique
multistep pathway requiring MMP14 and tissue inhibitor of
metalloproteinase 2 (TIMP2).13 14 Active MMP2 is, in turn, one
of the most efficient activators of MMP9.7 8 13 Gelatinase
activity is subsequently modulated by interaction with their
natural inhibitors, TIMPs, by forming noncovalent 1:1 stoichio-
metric complexes. TIMP2 preferentially inhibits MMP14 and
MMP2, whereas TIMP1 is a potent inhibitor of MMP9.8 13
Gelatinases are known to be expressed in GCA.15–19 However,
molecules modulating gelatinase activity such as MMP14 or
TIMPs have not been evaluated or have been detected in only a
few cases. In order to gain a better understanding of the
physiopathological role of gelatinases in GCA, the aims of our
study were to investigate the expression and distribution of
gelatinases, TIMPs and MMP2-activator MMP14 at the mRNA
and protein level, and to determine gelatinase activation status
and resulting proteolytic activity in GCA lesions.
PATIENTS AND METHODS
Patients
We studied 46 patients with biopsy-proven GCA. Thirty-three
patients had received no treatment before the temporal artery
excision, whereas the remaining 13 had received 1 mg/kg/day
of prednisone for 9¡2.5 days (mean ¡ SEM). Unless other-
wise indicated, only treatment-naive patients were considered
in quantitative measurements. Twelve normal temporal arteries
from patients in whom GCA was initially considered but
Abbreviations: GCA, giant-cell arteritis; IEL, internal elastic lamina;
VSMC, vascular smooth muscle cells
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subsequently excluded served as controls. In all of them,
symptoms were related to other conditions, and in none of
them was the clinical suspicion strong enough to prescribe
treatment in spite of a negative biopsy. The study was approved
by the Ethics Committee of our institution, and all patients
signed informed consent.
Specimens were embedded in OCT, snap-frozen in iso-
penthane prechilled in liquid nitrogen and stored at 280 C˚.
Additional fragments from 6 patients and 2 controls were
directly frozen in liquid nitrogen and stored at 280 C˚ in order
to perform gelatin zymography and western-blot analysis.
Histopathological evaluation
Temporal artery biopsies were classified according to the
extension of inflammatory infiltrates. Sixteen specimens had
inflammatory infiltrates limited to the vasa vasorum and
adventitial layer. The remaining 30 had fully developed lesions
with inflammatory infiltrates extending through the entire
artery wall. The topographic distribution of MMPs was
separately evaluated in both groups. Additional aspects
evaluated were IEL integrity and extent of intimal hyperplasia.
Elastic lamina was stained with 1% Shikata’s orcein (Scharlau
Chemie S.A., Barcelona, Spain) in 70% ethanol. IEL disruption
was scored as follows: 1, IEL preserved in .80% of the
circumference; 2, IEL preserved in 50–80%; 3, IEL preserved in
30–50%; and 4, IEL remaining in ,30%. Intimal hyperplasia
was scored from 0 to 4 as described.5
Immunostaining
Serial 4–6-mm temporal artery sections from the 46 patients and
12 controls were incubated with the following primary
antibodies: monoclonal mouse antihuman MMP9 (clone GE-
213) (Chemicon International, Inc., Temecula, CA) at 1/1000
dilution, polyclonal rabbit antihuman MMP2 (Chemicon) at 1/
500 dilution, polyclonal rabbit antihuman MMP14 (Chemicon)
at 1/250 dilution, monoclonal mouse antihuman TIMP1 (clone
Ab-2) (Calbiochem, Cambridge, MA) at 1/40 dilution and
monoclonal mouse antihuman TIMP2 (clone Ab-1)
(Calbiochem) at 1/40 dilution. Immunoglobulins obtained from
the same species were used as negative controls.
Immunodetection was carried out with an HRP-labelled
polymer conjugated to secondary antibodies (EnVision kit from
Dako, Carpinteria, CA), as reported.20 21
Quantification of the immunostaining at the granulomatous
area was performed in the 30 specimens with fully developed
lesions according to a semiquantitative 0–4 score, as
described.20 21
mRNA quantification
Total RNA was obtained from 150 serial sections (5 mm thick)
per biopsy using TRIzol (Invitrogen, Carlsbad, CA). RNA could
be obtained from 35 patients (27 untreated and 8 treated) and
from the 12 controls. One microgram of total RNA was reverse-
transcribed to cDNA using the Archive kit (Applied Biosystems,
Foster City, CA). Samples were stored at 220 C˚ until use.
MMP2, MMP9, MMP14, TIMP1 and TIMP2 expression was
measured by real-time quantitative PCR using specific Assay-
on-Demand Taqman Gene expression probes from Applied
Biosystems.20 21
Film in situ zymography (FIZ)
Topographic distribution of gelatinase activity was assessed by
FIZ (Fuji Photo Film Co., Ltd, Tokyo, Japan). Five-micrometre-
thick cryostat sections from the same biopsy samples used for
immunostochemistry were applied to 7-mm polyester mem-
branes cross-linked with gelatin or with gelatin containing the
gelatinase inhibitor (1,10)-phenanthroline as a control for
specificity. Films were incubated for 20 h in a moist chamber at
37 C˚ and stained with 0.5% Amido Black 10B (Sigma) in 70%
methanol, 10% acetic acid for 10 min and distained by washing
in 70% methanol, 10% acetic acid. Gelatinase activity was
visualised as destained areas on a dark-blue background.
Gelatin zymography
Frozen temporal artery samples (0.5 cm long) from 6 patients
and 2 controls, were homogenised in 1 ml of TRIzol. Given the
substantial amount of tissue required, this study could not be
extended to more specimens. One hundred micrograms of total
protein per sample, extracted according to the manufacturer’s
instructions, was subjected to gelatin zymography as
described.22 23
Western-blot
Twenty micrograms of protein obtained from the homogenised
arteries was subjected to SDS-PAGE and transferred onto
nitrocellulose. Membranes were incubated overnight at 4 C˚
with a polyclonal rabbit antihuman MMP14 (Chemicon) at
1:1000 dilution. Immunodetection was performed as published.23
Statistics
The Mann–Whitney U test was used to compare quantitative
variables and Spearman test for correlations, and the Fisher
exact test was used for contingency tables.
RESULTS
MMP expression in temporal artery biopsies from
patients with GCA and controls
No MMP9 or MMP14 expression was detected by immunohis-
tochemistry in normal arteries. In contrast, MMP2 was
expressed by vascular smooth muscle cells (VSMC) in the
medial layer, as previously observed15–17 19 (fig 1). MMP9 and
MMP14 mRNA were detected at low concentrations in normal
biopsies but were significantly more abundant in samples from
patients with GCA (fig 2). No differences were found in MMP2
mRNA between patients and controls, further supporting
constitutive MMP2 expression in non-inflamed arteries.
MMP9 and MMP14 were detected by immunohistochemistry
in all specimens with GCA lesions and were mainly expressed
by inflammatory cells. Although, at the mRNA level, no
differences were found in MMP2 expression between patients
and controls, immunostaining revealed important differences
in MMP2 distribution. In normal arteries, MMP2 was mainly
expressed by VSMC, whereas in GCA specimens MMP2 was
expressed not only by remaining VSMC but also, and more
intensively, by infiltrating leucocytes (fig 1). The pattern of
MMP expression varied according to the extent of inflamma-
tory involvement (fig 1). In specimens with inflammatory
infiltrates restricted to vasa vasorum and adventitial layer,
MMPs were expressed by adventitial inflammatory cells, and
MMP2 was also expressed by preserved VSMC at the media,
similarly to normal arteries. In GCA arteries with fully
developed lesions, VSMC were destroyed, and MMPs were
intensively expressed by the granulomatous infiltrates at the
media and intima/media junction. MMP2, MMP9 and MMP14
were also expressed by myointimal cells at the hyperplasic
intima (fig 1).
Immunostaining scores for all 3 MMPs were significantly
correlated (MMP2 vs MMP9, r = 0.80, p,0.0001; MMP2 vs
MMP14, r = 0.78, p,0.0001; MMP9 vs MMP14, r = 0.78,
p,0.0001). In accordance with previous studies showing
coordinated expression of MMP2 and MMP14,22 23 a significant
correlation between MMP2 and MMP14 mRNA was observed
(r = 0.39, p = 0.048). Intriguingly, there was a negative
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correlation between MMP2 and MMP9 mRNA concentration
(r =20.45, p = 0.019).
Activation status of MMPs in GCA
In order to assess the activation status of gelatinases in GCA
lesions, temporal artery protein extracts were subjected to
gelatin zymography (fig 3A). Interestingly, in control arteries,
both MMP9 and MMP2 pro-enzymes could be detected by this
sensitive method, even though immunohistochemistry was
only able to detect MMP2. No activated forms of gelatinases
were detected in normal samples. In contrast, in fully inflamed
arteries, activated forms of both gelatinases were present.
Interestingly, in the artery with inflammatory infiltrates
restricted to the adventitia with a preserved media, the
activated form of MMP9 was apparent, but MMP2 was mostly
present in its latent form, as in control arteries (fig 3A).
MMP14 detection by western blot in temporal artery biopsy
extracts disclosed a 45-kDa form in addition to the 57-kDa
active species (fig 3B). The 45-kDa form is inactive and results
from proteolytic removal of the catalytic domain of MMP14 by
active MMP2 and by active MMP14 itself.24 25 This constitutes a
counter-regulatory mechanism limiting MMP14 activity. The
generation of the 45-kDa form requires, thus, full activation of
the MMP14/MMP2 system, and its detection in lesions further
indicates that the MMP2/MMP14 system is functionally
operative. As shown in fig 3B, active MMP14 and particularly
its 45-kDa form were more abundant in GCA patients than in
controls.
TIMP counterbalance
Like MMP2, its inhibitor TIMP2 was constitutively expressed by
VSMC in normal biopsies, at both the mRNA and protein level
(fig 4 and on-line figure). As mentioned, TIMP2 is necessary for
MMP2 activation by MMP14.13 14 Constitutive TIMP2 expres-
sion guarantees that MMP2 can be activated when required
but, at the same time, maintains constitutive MMP2 function-
ally inactive in quiescent arteries.
In GCA samples, TIMP1 mRNA was significantly upregu-
lated, whereas TIMP2 mRNA significantly decreased compared
with controls (fig 4). Immunohistochemical analysis showed
that, in GCA biopsies, TIMP1 was expressed by inflammatory
cells, whereas TIMP2 was expressed by both VSMC and
infiltrating leucocytes (on-line figure). Distribution of gelati-
nases was, thus, coincident with that of their respective
inhibitors and may constitute a counter-regulatory mechanism
restricting the destructive potential of gelatinases, However, the
MMP9/TIMP1 and MMP2/TIMP2 mRNA ratios were signifi-
cantly higher in GCA specimens compared with controls (fig 4).
In agreement with this observation, the intensity and extent of
immunostaining were lower for TIMPs than for MMPs. MMP9
median score was 3 (range 1–4), whereas the TIMP1 median
score was 2 (range 1–3); p = 0.015. The MMP2 median score
was 3 (range 1–4), whereas the TIMP2 median score was 2 (1–
3); p = 0.03. (on-line figure). These findings indicate that, in
inflammed arteries, MMP/TIMP balance favours proteolytic
activity.
Gelatinolytic activity of MMP2 and MMP9 in GCA
As shown in fig 5, in accordance with the inactive status of
MMP2 expressed by VSMC, normal temporal arteries did not
exhibit proteolytic activity. In arteries with inflammatory
infiltrates limited to the adventitia, a weak gelatinolytic activity
could be observed in areas with inflammatory infiltrates. No
gelatinolytic activity could be observed in the media, as in
control specimens. In fully developed lesions, a strong
gelatinolytic activity was observed in inflamed zones, particu-
larly in granulomatous areas at the media and at the intima/
media junction. Myointimal cells also exhibited proteolytic
activity (fig 5). Gelatinase activity, thus, required co-expression
of MMP-9, MMP2 activator MMP14 and activated MMP2,
which in turn may activate MMP9. According to the elevated
MMP/TIMP ratio observed, colocalisation of MMPs with their
respective inhibitors did not prevent gelatinolytic activity (on-
line figure). Unfortunately, this system could not discern how
much MMP9 or MMP2, respectively, contributed to the
resulting proteolytic activity.
Effect of corticosteroids on MMP expression
Samples from patients who had received corticosteroids had
significantly lower immunohistochemical scores for MMPs
than samples from untreated patients (fig 6). However, no
significant differences in MMP2 and MMP14 mRNA levels
Figure 1 Expression of MMP2, MMP9 and
MMP14 in serial sections of temporal arteries
from controls and from patients with GCA,
according to the extent of inflammatory
infiltrates. In specimens with inflammatory
infiltrates involving vasa vasorum and
adventitia only, MMP expression was similar
to controls, with some MMP2 and MMP9
expression by inflammatory cells (arrows). In
fully developed lesions, expression
predominates at the granulomatous areas.
MMP expression by myointimal cells
surrounding the lumen can also be observed
(arrowheads).
MMP2 and MMP9 activity in GCA 1431
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could be found between untreated patients and those who had
received treatment (MMP2: 1.02 (0.23–4.67) vs 1.43 (0.58–
6.93), p = 0.43; MMP14: 1.44 (0.55–2.54) vs 1.32 (0.83–2.48),
p = 0.81). MMP9 mRNA clearly tended to decrease, but the
difference did not reach statistical significance (11.74 (0.59 –
34.78) vs 5.08 (2.29–23.55), p = 0.11).
Potential role of gelatinases both in vascular
destruction and vascular remodelling
High (3–4) IEL disruption scores were significantly more
frequent in temporal arteries with fully developed lesions than
in those with adventitial inflammation only (OR 31, 95% CI
3.02–329.1, p = 0.0011), supporting a relevant elastinolytic
activity of macrophages at the granulomatous area. The
participation of MMP2 and MMP9 in this process is supported
by the localisation of maximal gelatinolytic activity in the
granulomatous area. IEL rupture positively correlated with the
extent of intimal hyperplasia (r = 0.5, p = 0.036), suggesting
that, through MMP expression, myointimal cells may contribute
and, at the same time, take advantage of the breakdown of IEL to
migrate towards the intima.
However, in samples with fully developed lesions, no
significant correlation was observed between MMP immuno-
histochemical scores and IEL disruption scores (MMP9 r = 0.22,
p = 0.38; MMP2 r = 0.34, p = 0.17; MMP14 r = 0.22, p = 0.38)
or intimal hyperplasia scores.
DISCUSSION
Gelatinase expression has been previously reported in GCA,15–19
but this is the first attempt to investigate gelatinase functional
regulation and activity. Indeed, gelatinase expression was not
always associated with enzymatic activity. Normal specimens
and samples with infiltrates restricted to the adventitia did not
disclose gelatinolytic activity in the media in spite of significant
MMP2 expression by VSMC. These findings indicate that
constitutively expressed MMP2 is not functionally active and
that additional stimuli (ie, inflammation or injury) are required
for its activation. As shown by gelatine zymography, MMP2
was produced, indeed, as a pro-enzyme in normal arteries
whereas, in GCA lesions, MMP2 was activated, likely as a
consequence of concomitant induction of MMP14. Moreover,
MMP2 inhibitor TIMP2, intensively expressed by VSMC in
normal specimens, decreased in GCA, favouring MMP-2
proteolytic balance in inflamed arteries.
MMP9 was strongly upregulated and activated in GCA.
MMP9 inhibitor TIMP1, which is induced by inflammatory
mediators,26 was also upregulated in GCA. However, MMP9/
TIMP1 ratio favoured proteolysis in lesions. Maximal gelatino-
lytic activity occurred in areas where coexpression of the three
MMPs investigated was observed in inflammatory or in
myointimal cells. These findings suggest that gelatinolytic
activity in GCA requires coordinated regulation of the whole
Figure 2 MMP9, MMP2 and MMP14 mRNA concentrations in temporal
arteries from 27 untreated GCA patients and 12 controls.
Figure 3 Activation status of MMPs. (A) Gelatin zymography of temporal
artery extracts disclosing gelatinolytic bands corresponding to zymogens
and activated forms of MMP2 and MMP9. Lanes 1–2 are controls, lanes 3–
7 samples with fully developed lesions, and lane 8 corresponds to a
specimen with adventitial inflammation only. (B) Detection of MMP14 in the
same samples by western blot.
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system: increased expression of MMP9 and MMP14, activation
of MMP2 by MMP14, subsequent activation of MMP9 by
MMP2, and absolute or relative downregulation of TIMPs.
Although, at the protein level, there was a positive correlation
between MMP2, MMP9 and MMP14 expression scores in
granulomatous areas, a negative correlation between MMP2
and MMP9 transcripts was observed. Since MMP9 is mainly
expressed by infiltrating leucocytes, increased MMP9 tran-
scripts may indicate intense inflammatory activity, resulting in
destruction of the medial layer and decreasing the contribution
Figure 4 TIMP1 and TIMP2 mRNA concentrations in temporal arteries from 27 untreated GCA patients and 12 controls. MMP9/TIMP1 and MMP2/TIMP2
ratios in the same specimens.
Figure 5 Gelatinolytic activity of MMP2 and MMP9 according to the extension of inflammatory infiltrates. In spite of strong MMP2 expression in the media
of normal temporal arteries and of specimens with adventitial inflammation only, gelatinolytic activity appears only in the areas with inflammatory infiltrates
(arrows). Activity is maximal in fully developed lesions, particularly at the granulomatous areas (arrowheads). Gelatinolytic activity can also be observed in
the hyperplastic intima of fully developed lesions.
MMP2 and MMP9 activity in GCA 1433
www.annrheumdis.com
 group.bmj.com on July 11, 2011 - Published by ard.bmj.comDownloaded from 
of VSMC to MMP2 expression. Moreover MMP2-deficient mice
have increased production of MMP9, and a negative regulation
of MMP2 on MMP9 expression has been demonstrated.27 28
Production of active MMPs by infiltrating leucocytes may be
crucial in the development of vascular inflammation by
allowing leucocyte progression across the vessel wall.29 30
Moreover, gelatinases modulate bioavalability and cleavage of
many cytokines, chemokines and growth factors, resulting in
additional regulatory functions in inflammatory diseases. The
recent observation that MMP2-null mice develop more severe
lesions in various models of chronic inflammatory diseases27 28
indicates that the roles of MMPs in inflammation are far more
complex than anticipated.
Gelatinases may contribute to vessel-wall disruption in GCA,
which may convey severe complications such as the develop-
ment of aneurysms. Maximal gelatinolytic activity occurred in
the granulomatous areas where activated macrophages have
been demonstrated to have additional destructive activities,
such as production of reactive oxygen species and nitric oxide.31
This location suggests, indeed, a role for gelatinases in the
destruction of IEL. In fact, specimens with adventitial
inflammation only, which had no gelatinolytic activity at the
media, had significantly more preserved IELs than arteries with
fully developed lesions, which showed significant enzymatic
activity at the intima/media junction. However, in specimens
with fully developed lesions, no correlation was found between
the intensity of gelatinase expression and the extent of IEL
disruption. This observation indicates that regulation of MMP
enzymatic activity may have a stronger functional impact than
regulation of MMP expression. Moreover, elastin-degrading
enzymes produced in the granulomatous area may include
enzymes other than MMP2 or MMP9.
In specimens with fully developed inflammatory lesions,
myointimal cells also expressed MMPs. The development of
intimal hyperplasia is a significant source of morbidity in
patients with vasculitis.1 5 However, it provides a mechanism
reinforcing the vessel wall when IEL is destroyed. Intimal
hyperplasia correlated, indeed, with the extent of IEL disrup-
tion, as observed by others.32 IEL degradation may promote
intimal hyperplasia by facilitating myointimal cell activation
and migration towards the intima.1 2 33 However, in arteries
with fully developed lesions, no significant correlation was
found between the extent of intimal hyperplasia and the
intensity of MMP expression. MMP may have a dual function
in vascular remodelling: by disrupting IEL may promote and
allow myointimal cell migration but, at the same time,
increased MMP expression and activity may prevent excessive
matrix deposition and lumen occlusion.
Immunostaining scores at the granulomatous area were
significantly lower in samples from patients who had received
corticosteroids. Interestingly, although MMP9 mRNA tended to
decrease, no significant differences were found in MMP mRNA
concentrations. Corticosteroids exert post-transcriptional and
post-translational regulatory activities, which may regulate
protein and mRNA levels differently,34–36 and the treatment period
may not have been long enough to downregulate the whole
system efficiently. Moreover, although MMP expression in
granulomatous areas may decrease upon corticosteroid treatment,
MMP, and particularly MMP2, mRNA may be upregulated in
regenerating VSMC during the process of vascular repair.
In summary, increased MMP expression and activity are
prominent in GCA. The pattern of MMP expression and activity
supports complex roles not only in vessel-wall inflammation
and disruption, but also in vascular remodelling and repair. A
better understanding of the specific roles of various MMPs at
different disease stages is necessary before MMPs can be
considered therapeutic targets to limit vessel inflammation and
destruction in GCA.
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